The thyroid gland disorder treatment market is set to grow by USD 632.05 million at a CAGR of 4.63% from 2020 to 2025, according to the latest research report from Technavio.
For more insights on the thyroid gland disorder treatment market - Request a Free Sample Report!
The thyroid gland disorder treatment market covers the following areas:
Thyroid gland disorder treatment market - Driver
The key factor driving growth in the thyroid gland disorder treatment market is the rise in thyroid treatment awareness programs globally. To increase the awareness towards timely diagnosis and treatment of thyroid gland disorders, the governmental and non-governmental organizations are increasingly launching campaigns that are focused on educating the people for timely detecting the preliminary symptoms that can develop into complex thyroid disorders. Frequent launches of such awareness programs worldwide are driving individuals toward the efficient treatment of thyroid gland disorders, thereby promoting the growth of the thyroid gland disorder treatment market.
Thyroid gland disorder treatment market - Challenge
The high entry barrier will be a major challenge for the thyroid gland disorder treatment market during the forecast period. The thyroid gland disorder treatment market has the presence of many established players, stringent regulations, and stringent compliance requirements for product commercialization, which makes it difficult for smaller companies to come up with innovative products. This sets the high entry barrier for new players. The drugs used for the treatment of thyroid gland disorder requires careful manufacturing technique, which is either patented or trade secrets of the companies. New players face challenges in achieving such perfection in manufacturing the drugs. The other hurdle for the market entry is to maintain long-established relationships with the marketing teams of leading vendors with the physicians.
Thyroid gland disorder treatment market - Segmentation
The Thyroid Gland Disorder Treatment Market is segmented by Type (hypothyroidism and hyperthyroidism) and Geography (North America, Europe, Asia, and ROW).
The thyroid gland disorder treatment market share growth by the hypothyroidism segment will be significant for revenue generation. The increasing awareness about the timely diagnosis of chronic diseases is driving the demand for efficient treatment options, which is promoting the sales growth of commercially available medications for treating hypothyroidism. The chronic nature of hypothyroidism, coupled with its increasing prevalence, has resulted in a surge in demand for medications and treatment in the hypothyroidism segment.
Companies Mentioned
The thyroid gland disorder treatment market is fragmented and the vendors are deploying growth strategies such as investing in R&D for the design, development, and manufacturing of novel therapeutics to compete in the market.
- Abbott Laboratories
- AbbVie Inc.
- Alvogen ehf
- Amgen Inc.
- GlaxoSmithKline Plc
- Lannett Co. Inc.
- Merck KGaA
- Pfizer Inc.
- RLC Labs Inc.
- Viatris Inc.
Subscribe to our "Lite Plan" billed annually at USD 3000 to join a community, who are eligible to view 3 reports monthly and download 3 reports annually.
Related Reports:
Endocrinology Drugs Market -The endocrinology drugs market has the potential to grow by USD 25.25 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.26%. Download a free sample now!
Liposomal Products Market -The liposomal products market share should rise by USD 2.21 billion from 2021 to 2026 at a CAGR of 7.81%. Download a free sample now!
Thyroid Gland Disorder Treatment Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.63% |
Market growth 2021-2025 |
USD 632.05 million |
Market structure |
Fragmented |
YoY growth (%) |
3.97 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 35% |
Key consumer countries |
US, Canada, Germany, China, and UK |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Abbott Laboratories, AbbVie Inc., Alvogen ehf, Amgen Inc., GlaxoSmithKline Plc, Lannett Co. Inc., Merck KGaA, Pfizer Inc., RLC Labs Inc., and Viatris Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized |
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article